1358-GABA-Driven Immunotherapy Resistance in Tumors
Recent research by Hernández-Verdin et al. reveals that tumor-derived GABA acts as a metabolic barrier to immunotherapy success in patients whose tumors contain tertiary lymphoid structures (TLSs). Although these structures usually indicate a positive response to treatment, high levels of GABA create a dysfunctional immune environment that leads to therapeutic resistance. The study identifies specific proximal tubule-like tumor cells as the primary source of this neurotransmitter, which suppresses B cell maturation and antibody production. By integrating spatial transcriptomics and metabolic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.